These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor. Holwerda KM; Burke SD; Faas MM; Zsengeller Z; Stillman IE; Kang PM; van Goor H; McCurley A; Jaffe IZ; Karumanchi SA; Lely AT J Am Soc Nephrol; 2014 Apr; 25(4):717-25. PubMed ID: 24335973 [TBL] [Abstract][Full Text] [Related]
23. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. Zhang ZF; Wang T; Liu LH; Guo HQ PLoS One; 2014; 9(3):e90135. PubMed ID: 24621598 [TBL] [Abstract][Full Text] [Related]
24. Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review. Hanna RM; Ahdoot RS; Kim MS; Jhaveri KD; Kalantar-Zadeh K; Kurtz IB Curr Opin Nephrol Hypertens; 2022 Jan; 31(1):47-56. PubMed ID: 34750330 [TBL] [Abstract][Full Text] [Related]
25. A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib. Li A; Ambruso SL; Oto OA; Barry M; Edelstein CL BMC Nephrol; 2022 Jul; 23(1):264. PubMed ID: 35870899 [TBL] [Abstract][Full Text] [Related]
26. Both New-Onset and Pre-Existing Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy. Moriyama S; Hieda M; Kisanuki M; Kawano S; Yokoyama T; Fukata M; Kusaba H; Maruyama T; Baba E; Akashi K; Fukuda H Circ J; 2024 Jan; 88(2):217-225. PubMed ID: 36476830 [TBL] [Abstract][Full Text] [Related]
27. Preeclampsia and eclampsia: the conceptual evolution of a syndrome. Erez O; Romero R; Jung E; Chaemsaithong P; Bosco M; Suksai M; Gallo DM; Gotsch F Am J Obstet Gynecol; 2022 Feb; 226(2S):S786-S803. PubMed ID: 35177220 [TBL] [Abstract][Full Text] [Related]
28. [Bevacizumab and arterial hypertension or proteinuria: management]. Senellart H; Bennouna J Rev Mal Respir; 2008 Jun; 25(6):767-72. PubMed ID: 18772832 [TBL] [Abstract][Full Text] [Related]
29. Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidney. Li J; Li XL; Li CQ Am J Med Sci; 2023 Dec; 366(6):404-412. PubMed ID: 37699444 [TBL] [Abstract][Full Text] [Related]
30. Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors. Thompson LA; Saseen JJ; O'Bryant CL; Allen RR; Nair KV J Oncol Pharm Pract; 2015 Aug; 21(4):258-67. PubMed ID: 24727344 [TBL] [Abstract][Full Text] [Related]
31. Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma. Jaimes EA Semin Nephrol; 2020 Jan; 40(1):49-58. PubMed ID: 32130966 [TBL] [Abstract][Full Text] [Related]
32. Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan. Tanaka H; Takahashi K; Yamaguchi K; Kontani K; Motoki T; Asakura M; Kosaka S; Yokomise H; Houchi H Biol Pharm Bull; 2018; 41(4):644-648. PubMed ID: 29607938 [TBL] [Abstract][Full Text] [Related]
33. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Izzedine H; Rixe O; Billemont B; Baumelou A; Deray G Am J Kidney Dis; 2007 Aug; 50(2):203-18. PubMed ID: 17660022 [TBL] [Abstract][Full Text] [Related]
34. [Nephrotoxicity--proteinuria and hypertension--]. Ando M Gan To Kagaku Ryoho; 2008 Oct; 35(10):1649-53. PubMed ID: 18931564 [TBL] [Abstract][Full Text] [Related]
35. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Horsley L; Marti K; Jayson GC Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844 [TBL] [Abstract][Full Text] [Related]
36. Glucocorticoid diminishes vascular endothelial growth factor and exacerbates proteinuria in rats with mesangial proliferative glomerulonephritis. Ha IS; Um EY; Jung HR; Park HW; Cheong HI; Choi Y Am J Kidney Dis; 2002 May; 39(5):1001-10. PubMed ID: 11979343 [TBL] [Abstract][Full Text] [Related]
37. Renal Implications of Long-Term Systemic Bevacizumab for Recurrent Respiratory Papillomatosis. Robinson CH; Hart-Matyas M; Morgenstern DA; Noone D; Campisi P Ann Otol Rhinol Laryngol; 2024 Jan; 133(1):119-123. PubMed ID: 37439024 [TBL] [Abstract][Full Text] [Related]
38. Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials. Zhang W; Feng LJ; Teng F; Li YH; Zhang X; Ran YG Expert Rev Clin Pharmacol; 2020 Mar; 13(3):311-320. PubMed ID: 32105149 [No Abstract] [Full Text] [Related]